JGR Capital Partners Orgenesis Latest Research (ORGS)

This page is dedicated to JGR Capital’s Orgenesis Latest Research.

Orgenesis is a biopharmaceutical company with a focus on cell therapy development and manufacturing. The company focuses primarily on assisting insulin-dependent diabetes patients. Orgenesis trades as ORGS on OTCMKTS. The biopharmaceutical firm was founded in 2008 in Maryland, where its headquarters remain.

Latest Research

Company Overview

Orgenesis Inc. is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company's subsidiary, MaSTherCell SA, which specializes in cell therapy development for advanced medicinal products. MaSTherCell is providing two types of services to its customers: process and assay development services and good manufacturing practice (GMP) contract manufacturing services. The CTB activity is based on its technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into pancreatic beta cell-like insulin producing cells for patients with Type I Diabetes. It intends to advance a product that combines cell-based therapy and regenerative medicine, Autologous Insulin Producing (AIP) cells, into clinical development.

Market Data

0.370
0.000 (0.00%)
Oct 20 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.37 - 0.40
52 week 0.28 - 0.98
Open 0.40
Vol / Avg. 10,500.00/24,960.00
Mkt cap 45.06M
P/E     -
Div/yield     -
EPS -0.14
Shares 121.78M
Beta -6.23
Inst. own 9%

Key Stats

Q3 (Aug '17) 2016
Net profit margin -76.23% -143.72%
Operating margin -133.18% -176.29%
EBITD margin - -130.01%
Return on average assets -21.26% -25.46%
Return on average equity -74.08% -71.84%
Employees 1 -
CDP Score - -

Officers and directors

Vered Caplan Chairman of the Board, Chief Executive Officer, President; Chief Executive Officer of Orgenesis Maryland Inc.
Age: 46
Neil T. Reithinger CPA Chief Financial Officer, Treasurer, Secretary
Age: 46
Sarah Ferber Ph.D. Chief Scientific Officer
Age: 60
Yaron Adler Director
Age: 44
Hugues Bultot Director
David Sidransky M.D. Director
Age: 56
Guy Yachin Director
Age: 47

 

For more information on Orgenesis:

Access Orgenesis’ Home Page